Fig.2
One-way sensitivity analysis of sorafenib versus lenvatinib (INMBs) disc_rate discount rate, HFSR hand-foot skin reaction, INMB incremental net monetary benefits; NMB, net monetary benefits, PartSA partitioned survival analysis, PD progressive disease, PF progression free